Dr Reddys Laboratories (RDY) Total Debt (2009 - 2026)

Dr Reddys Laboratories (RDY) has reported Total Debt for 10 consecutive years, with $760.0 million the latest figure, recorded in Q1 2026.

• Quarterly Total Debt rose 41.53% year-over-year to $760.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $760.0 million (up 41.53% YoY) and the FY2026 annual result came in at $760.0 million, up 41.53% from the prior year.
• Total Debt grew to $760.0 million in Q1 2026 per RDY's latest filing, from $537.0 million in the prior quarter.
• Over the last five years, Total Debt for RDY reached as high as $760.0 million in Q1 2026 and fell as low as $88.0 million in Q1 2024.
• A 5-year average of $316.0 million and a median of $106.0 million in 2023 frame the typical range for Total Debt.
• Annual changes were most pronounced in 2024 — Total Debt retreated 16.98% — and 2025, when it jumped 510.23%.
• Year by year, Total Debt stood at $89.0 million in 2022, then increased by 19.1% to $106.0 million in 2023, then dropped by 16.98% to $88.0 million in 2024, then soared by 510.23% to $537.0 million in 2025, then jumped by 41.53% to $760.0 million in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $760.0 million, $537.0 million, and $88.0 million for Q1 2026, Q1 2025, and Q1 2024 respectively.